Q2 EPS Forecast for X4 Pharmaceuticals Raised by Analyst

Key Points

• Brookline Capital Markets raised its Q2 2026 EPS estimate for X4 Pharmaceuticals to $(0.20) from $(0.23), reflecting slightly improved expectations ahead of the quarter.
• X4 Pharmaceuticals beat Wall Street estimates in its latest earnings report, posting EPS of $(0.16) versus the expected $(0.20), though revenue of $2.71 million came in below the $3.20 million consensus.
• Analyst sentiment is mixed: the stock has a Hold consensus rating and an average price target of $8.50, while institutional ownership remains high at 72.03%.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Equities research analysts at Brookline Capital Markets raised their Q2 2026 earnings estimates for shares of X4 Pharmaceuticals in a research note issued on Wednesday, May 6th. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings of ($0.20) per share for the quarter, up from their previous estimate of ($0.23). The consensus estimate for X4 Pharmaceuticals' current full-year earnings is ($0.77) per share. Brookline Capital Markets also issued estimates for X4 Pharmaceuticals' Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at ($0.95) EPS.

Several other analysts also recently weighed in on the stock. Guggenheim assumed coverage on shares of X4 Pharmaceuticals in a research report on Monday, March 9th. They set a "buy" rating and a $12.00 target price on the stock. Weiss Ratings downgraded shares of X4 Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday. Finally, Wall Street Zen raised shares of X4 Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, March 21st. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $8.50.

X4 Pharmaceuticals Price Performance

NASDAQ:XFOR opened at $4.43 on Monday. The company has a market cap of $417.84 million, a PE ratio of -0.98 and a beta of 0.31. X4 Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $4.83. The company has a current ratio of 10.18, a quick ratio of 9.98 and a debt-to-equity ratio of 0.45. The company's 50 day moving average is $4.03 and its two-hundred day moving average is $3.82.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. The company had revenue of $2.71 million for the quarter, compared to the consensus estimate of $3.20 million. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%.

Institutional Trading of X4 Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in shares of X4 Pharmaceuticals in the 4th quarter valued at $90,000. Susquehanna Portfolio Strategies LLC purchased a new stake in shares of X4 Pharmaceuticals in the 4th quarter valued at $173,000. Perceptive Advisors LLC purchased a new stake in shares of X4 Pharmaceuticals in the 4th quarter valued at $25,258,000. Man Group plc purchased a new stake in shares of X4 Pharmaceuticals in the 4th quarter valued at $97,000. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of X4 Pharmaceuticals in the 4th quarter valued at $258,000. 72.03% of the stock is owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company's lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström's macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.